CONMED Corporation Announces Chief Financial Officer Transition

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the departure of Todd Garner from his role as Chief Financial Officer effective March 15, 2026. To ensure a smooth and orderly transition, Mr. Garner will remain with the Company in an advisory capacity through November 2, 2026.

CONMED has initiated a comprehensive search process, supported by a leading executive search firm, to identify its next Chief Financial Officer.

“On behalf of our Board and leadership team, I want to thank Todd for his many contributions to CONMED over the past eight years,” said Pat Beyer, President and Chief Executive Officer. “Todd has been instrumental in strengthening our financial foundation and supporting strategic initiatives that position CONMED for scalable, long-term growth. We are also grateful for his commitment to ensuring a seamless transition.”

“I am grateful to my CONMED colleagues over the past eight years. It has been rewarding to be part of such a high-quality, driven team that has dramatically improved the revenue growth and profitability of the company. I’m committed to a smooth transition, positioning CONMED for strong future success,” said Todd Garner.

CONMED is reaffirming its full-year 2025 consolidated revenue and adjusted EPS guidance issued on November 5, 2025. Mr. Garner’s planned departure is not the result of any disagreement regarding the Company’s financial statements or disclosures.

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2024, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.